These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8991107)

  • 21. [Risk factors for occurrence of ophthalmopathy in the course of Graves-Basedow disease].
    Sieradzki J; Katra B; Mirkiewicz-Sieradzka B
    Przegl Lek; 2000; 57(6):321-3. PubMed ID: 11107864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular manifestations in children and adolescents with thyrotoxicosis.
    Grüters A
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 5():S172-4. PubMed ID: 10614915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
    Chen DY; Chen TH
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid stimulating antibodies in patients with Graves' ophthalmopathy.
    Gomez JM; Soler J; Navarro MA
    Thyroidology; 1991 May; 3(2):59-61. PubMed ID: 1726901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective.
    Tallstedt L; Lundell G
    Thyroid; 1997 Apr; 7(2):241-5. PubMed ID: 9133694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporine in Graves' ophthalmopathy.
    Franson KL; Middleton RK
    DICP; 1991; 25(7-8):750-3. PubMed ID: 1949935
    [No Abstract]   [Full Text] [Related]  

  • 27. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The influence of treatment of progressive edematous infiltrative ophthalmopathy on intraocular pressure].
    Rutecka-Debniak A; Krzystolik Z; Pilarska K; Krzyzanowska-Swiniarska B; Syrenicz A; Jarema A
    Klin Oczna; 1999; 101(3):195-200. PubMed ID: 10526444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for the presence of a functional TSH-receptor in retroocular fibroblasts from patients with Graves' ophthalmopathy.
    Heufelder AE; Bahn RS
    Exp Clin Endocrinol; 1992; 100(1-2):62-7. PubMed ID: 1361450
    [No Abstract]   [Full Text] [Related]  

  • 30. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism.
    Kubota S; Gunji K; Ackrell BA; Cochran B; Stolarski C; Wengrowicz S; Kennerdell JS; Hiromatsu Y; Wall J
    J Clin Endocrinol Metab; 1998 Feb; 83(2):443-7. PubMed ID: 9467555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up.
    Barczyński M; Konturek A; Hubalewska-Dydejczyk A; Gołkowski F; Nowak W
    Br J Surg; 2012 Apr; 99(4):515-22. PubMed ID: 22287122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ophthalmopathy of Graves' disease: a comparison between patients treated surgically and patients treated with radioiodide.
    Hamilton RD; Mayberry WE; McConahey WM; Hanson KC
    Mayo Clin Proc; 1967 Dec; 42(12):812-8. PubMed ID: 5630560
    [No Abstract]   [Full Text] [Related]  

  • 33. Radioiodine therapy and Graves' ophthalmopathy.
    Bartalena L; Marcocci C
    Thyroid; 1996 Jun; 6(3):253. PubMed ID: 8837336
    [No Abstract]   [Full Text] [Related]  

  • 34. Association between Graves' ophthalmopathy and smoking.
    Balazs C; Stenszky V; Farid NR
    Lancet; 1990 Sep; 336(8717):754. PubMed ID: 1975927
    [No Abstract]   [Full Text] [Related]  

  • 35. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
    Krassas GE; Segni M; Wiersinga WM
    Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum antibodies reactive with eye muscle antigens and the TSH receptor in a euthyroid subject who developed ophthalmopathy and Graves' hyperthyroidism.
    Wall J; Barsouk A; Stolarski C; Kiljanski J; Stachura I; Nebes V; Peele K; Volpe R; Kennerdell J
    Thyroid; 1996 Aug; 6(4):353-8. PubMed ID: 8875760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of Graves ophthalmopathy in an incidence cohort.
    Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
    Ophthalmology; 1996 Jun; 103(6):958-62. PubMed ID: 8643255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Function of the hypophyseo-thyroid system in patients with post-thyrotoxic encephalo-ophthalmopathy].
    Oleĭnik VA; Epshteĭn EV; Luchitskiĭ EV
    Vrach Delo; 1988 Sep; (9):72-5. PubMed ID: 3213004
    [No Abstract]   [Full Text] [Related]  

  • 40. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy.
    Fatourechi V; Bartley GB; Eghbali-Fatourechi GZ; Powell CC; Ahmed DD; Garrity JA
    Thyroid; 2003 Dec; 13(12):1141-4. PubMed ID: 14751035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.